EDAP's clinical trial tests ultrasound waves on early stage prostate cancer

By Elaine Rigoli

Tampa, Fla., May 24 - EDAP TMS SA announced the start of U.S. clinical trial treatments at Duke University Medical Center, where researchers are testing the use of high-intensity sound waves to treat early stage prostate cancer.

The nonsurgical technique, which the company said is widely used in Europe, is not approved by the Food and Drug Administration for use in the United States.

The purpose of the trial is to test the safety and effectiveness of the technique, called high intensity focused ultrasound, as the initial treatment in men with newly diagnosed, localized prostate cancer.

EDAP said researchers will compare the technique with cryotherapy, a common treatment that involves freezing the prostate gland.

Based in Vaulx-en-Velin, France, EDAP develops minimally invasive medical devices primarily for the treatment of urological diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.